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So much has been written and talked about penicillin, that I
feel I am in serious danger of becoming like some other Australian
birds-they sing perfectly a short series of notes, but repeat them
so often that they become rather boring. So today I thought it
might be more interesting to put before you an account of some of
the work on the use in medicine of naturally occurring antibacterial
substances. There are still many misapprehensions on this subject,
and it is one of the fields in which some historical information is
of help in the orientation of one's ideas at the present time.
The use of the products of moulds for therapeutic purposes
goes back to primitive medicine; there is good evidence that green
moulds were especially cultivated in Central Europe for applica-
tion to wounds, and there is also some evidence that the Mayans in
Yucatan cultivated a mould that was called cuxum which was used
in medicine, though undoubtedly the Mexicans go too far in claim-
ing that the Mayans discovered penicillin. I have also come across
the use of one of the field fungi, a sort of puffball, which was used
by one of the Indian tribes in Brazil.
It was as long ago as 1852 that the first record of the use of a
micro-organism appeared in The Lancet-from a British general
practitioner named Mosse.2" He proposed to use yeast as a treat-
ment for furunculosis. I need hardly say that it is still a popular
treatment among some, although yeast has never been clearly shown
to produce an antibacterial substance, and if there is any therapeutic
benefit from its use, it is probably attributable to something else,
possibly the vitamin content.
In 1877 Pasteur and Joubert wrote the following, based on
some of their experiments:32
Neutral or slightly alkaline urine is an excellent medium for the bacteria.
If the urine is sterile and the culture pure the bacteria multiply so fast that
in the course of a few hours their filaments fill the fluid with a downy felt.
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But if when the urine is inoculated with these bacteria an aerobic organism,
for example one of the "common bacteria," is sown at the same time, the
anthrax bacterium makes little or no growth and sooner or later dies out
altogether. It is a remarkable thing that the same phenomenon is seen in
the body even of those animals most susceptible to anthrax, leading to the
astonishing result that anthrax bacteria can be introduced in profusion into
an animal, which yet does not develop the disease; it is only necessary to
add some "common 'bacteria" at the same time to the liquid containing the
suspension of anthrax bacteria. These facts perhaps justify the highest hopes
for therapeutics.
These authors did not pursue their investigations. In 1885,
however, in Paris, Babes clearly demonstrated in liquid as well as
on solid media that one organism can elaborate a chemical sub-
stance which will stop the growth of another and stated that the
continued and widespread study of this reciprocal action of one
bacteriumion another might perhaps lead to therapeutic application.
In the same year, Cantani, an Italian, in a paper entitled "A
Research on Bacterial Therapy,"5 utilized the idea of replacing a
hiarmful organism, the tubercle bacillus, in the tissues of the lungs
with an ill-defined, harmless organism (probably a mixed species)
called Bact. termo. He claimed good results in the treatment of
a case of tuberculosis by insufflating large amounts of cultures of this
organism into the lungs. This was the first example of an endeavor
to replace one organism by another.
In 1887 a Swiss, Garre,'7 introduced a method for disclosing
bacterial antagonism which differs very little, if at all, from methods
used at the present time. He wrote:
I inoculated on the untouched cooled [gelatin] plate alternate parallel
st okes of B. fluorescens and Staph. pyogenes. This was carried out so
that the distance between the inoculated strokes increased from 3 to 15 mm.
B. fluorescens grew more quickly. Its products of secretion diffused into
the surroundings and were completely inhibitory for the near-by staphylo-
coccal inoculation. . .. Thus it is not a question of overgrowth or crowding
out of one by another quicker-growing species, as in a garden where luxuri-
antly growing weeds kill the delicate plants. Nor is it due to the utilization
o. the available foodstuff by the more quickly growing organisms, rather
there is an antagonism caused by the secretion of specific, easily diffusible
substances which are inhibitory to the growth of some species but completely
ineffective against others.
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This method was illustrated in a figure (Fig. 2) in a paper by Frost,
an American, written in 1904,16 about which I shall have more to
say later.
The first photographic record of antibiosis was published in Kiel
in 1889 by Doehle9 (Fig. 1). It showed that anthrax bacilli which
had been sown throughout the solid medium in a Petri dish had
been inhibited by an organism called Micrococcus anthracotoxicus
which had been planted on ithe surface in the form of a square.
Thus, by 1889, the phenomenon of microbial antagonism was well
known and had been illustrated, and its causation was attributed to
the elaboration of chemical substances. Many of the workers had
had in mind the use olf this bacterial antagonism for therapeutic
purposes.
Another line of reasoning was based on the clinical observation
that certain chronic diseases sometimes improved strikingly after
an attack of erysipelas, and indeed, in 1883, Fehleisen'4 had treated
a case of lupus by injecting srtreptococci from a patient with ery-
sipelas. Emmerich" in 1887 did experimental work along tihese
lines and showed ithat it was possible to protect rabbits from dying
of anthrax by the simultaneous injection of a streptococcus from a
case of erysipelas.
It was the pursuit of this form of experiment which led to the
first use of a bacterial product in medicine. In 1889 Bouchard3
observed the same form of protection against experimental anthrax
in the rabbit followingthe use of B. pyocyaneus. Unconnected with
Bouchard's work, Honl and Bukovsky in 189922 applied the metabo-
lic products of this organism to 100 cases of ulcers of the leg, obtain-
ing what they described as excellent results. Emmerich and L6w2
in the same year introduced an extract made of old cultures of B.
pyocyaneus, which they called "pyocyanase," capable of lysing sus-
pensions of B. anthracis in vitro, and which was also bactericidal to
Bact. typhosum, C. diphtheriae, the staphylococcus, and P. pestis.
At first they attempted systemic administration of the substance in
experimental infections in animals, but it proved too toxic for this
purpose. There is a very large collection of literature-pharmaco-
logical, biochemical, and particularly clinical-at the beginning of
this century on this substance. Pyocyanase was used extensively
for applications to infected tissues, for example, abscesses were
treated by injection of the material into their cavities. It was also
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used for infections of the eyes, and it was injected into the cerebro-
spinal fluid. Its chief use was in the treatment of acute diphtheria
and of diphtheria carriers; a photographic record exists showing
it being sprayed into the throat of a diphtheria carrier, probably
by Emmerich himself. I have even found a thesis from Switzer-
land written in 1908 in which pyocyanase was used for treating
bovine mastitis by injection into the udder in a way exactly similar
to that employed more recently using gramicidin and penicillin.
At 'this time, too, the desirability of having a differential action
of antiseptics was recognized, that is to say, antiseptics should be
more harmful to -the bacterium than to the tissue cell. Escherich
wrote in 190613 concerning the search for such a substance:
The resumption of these endeavours first became possible when the march
of science made known to us substances which possessed a high bactericidal
capacity without at the same time harming the tissues as do previously known
antisep-tics. These are the bactericidal substances obtained from the autolysis
of bacteria to the existence and significance of which Emmerich and Low
first drew attention.
He was referring to pyocyanase. In spite of almost universal com-
mendation of this subs'tance, it gradually fell out of use, although
it was on sale in Germany certainly into the 1930's. Very likely
the reason for its disuse was that the commercial firm involved
put on the market inactive material, which was noted in 1928 and
again later. But it is interesting that as recently as 1943, Rake,
Jones, and McKee34 found that a good preparation of pyocyanase
inhibited the growth of Strep. pyogenes at a dilution of 1 in 24,000.
Interest in the products of Ps. pyocyanea, as it is now called, is
considerable at the present time, for Doisy and his colleagues have
recently isolated four crystalline antibiotics from it and work on
other substances produced by this organism is in progress in Sweden.
There is no question 'that the work on pyocyanase was the first
serious attempt to introduce an antibiotic into medicine. Practi-
cally all the ideas and the type of trials which have been conducted
wi'th penicillin were undertaken by the workers with pyocyanase.
Unfortunately their technique was not so good as that in use at
present and they were working with a substance which had marked
toxic properties.
While this work on pyocyanase was being actively pursued, other
104THERAPEUTIC USE OF MICRO-ORGANISMS
interesting studies on antibiosis were recorded; for example, in
1903, Lode described his experiments24 performed with an accidental
bacterial contaminant. He was preparing an agar plate to demon-
strate to his class the growth of Micrococcus tetragenus. There
was a contamination by an air bacterium, and he noted inhibition
of growth around this organism. He subcultured it and observed
an inhibitory effect. The bacterium produced a diffusible substance
which strongly inhibited the growth of anthrax bacilli and Staph.
aureus, but not Bact. coli or Friedlander's bacillus. Lode did com-
prehensive and painstaking investigations of the substance; he
showed that it was bactericidal, that it was an enzyme, though
thermolabile. It could -be dried .by vacuum distillation and was
soluble in alcohol but not in ether. Neither the micro-organism
nor its metabolic products were toxic to animals. He performed
experiments on artificial infection in mice but the product had no
chemotherapeutic effects.
A little later, in 1907, Maurice Nicolle29 clearly demonstrated
the existence of a bactericidal and bacteriolytic substance produced
by B. subtilis, and he used the bacteriolytic properties of this organ-
ism to dissolve micrococci in the preparation of vaccines which he
used on rabbits. A little later Rappin3 in France used the filtrates
of the spore-formers B. sisbtilis, B. mwsentericusc, and B. mega-
therium for experiments on tu'bercle bacilli. He showed that they
were capable of dissolving the tubercle bacillus and he was led to
try the effect of -bacterial filtrates on experimental tuberculosis in
animals. In an interesting description he claimed that even two
or three subcutaneous or intraperitoneal injections of a broth filtrate
from B. mesentericus were sufficient to protect guinea-pigs against
the development of experimental tuberculosis. We will come back
later to similar experiments conducted with mould products.
It is convenient now to consider some other examples of bac-
terial substitution therapies. In 1909 Schi0tz,38 a Dane, noticed
that a patient with a staphylococcal throat infection, wrongly diag-
nosed as diphtheria and placed in a diphtheria ward, did not develop
the disease. Schi0tz then deliberately sprayed suspensions of staphy-
lococci into the throats of carriers. He claimed good results.
There are many other examples of the use of this spray for the
same purpose, and other organisms such as the pneumo-bacillus of
Friedlander were also employed for this purpose. That the
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staphylococcus does produce an antibiotic was shown by Dujardin-
Beaumetz. In 1915 Colebrook8 suggested the use of the same idea,
for he had noticed that pneumococci inhibited the growth of
meningococci.
Perhaps the best known example of this replncement therapy
was that of Metchnikoff,25 who wished to replace what he considered
harmful organisms in the intestines by the Bulgarian lactobacillus.
There is an enormous literature on the use of this organism and
later of B. acidophilus. It is not perhaps so widely known that
these lactic acid-producing bacteria were used very extensively for
the treatment of septic infections. One example was the use made
in 1915 by Newman,28 who treated cases of cystitis by injecting lactic
acid bacilli in-to the bladder. Another example which was widely
used, and which reached the stage of commercial production, was
that of Nissle in 191630 who thought he could replace Bact. coli
in the intestines by utilizing another "stronger" strain of Bact. coli
which produced an antibacterial effect. This preparation of Baa.
coli was placed on the market under the name of "mutaflor," and
was alleged to be useful in a number of intestinal infections as well
as for constipation.
Suggestions of the same kind continued to be made and I have
recently read an article in a French journal in which it was pro-
posed to use B. subtilis for combating intestinal infections. There
is an interesting account of a test made as early as 1908 along this
line by Nitsch,3" who was then working in Paris. It was noted
that two towns in France, Lyons and Versailles, were relatively
free from cholera, and after weighing up the situation Nitsch con-
cluded that the only thing which was partaken of in common by all
the inhabitants of these towns was air. And so he looked in the
air for bacteria antagonistic to the cholera vibrio. He isolated 11
antagonistic bacteria from 220 strains examined in Versailles, and
4 from 253 from Paris. Nitsch apparently went back to Poland
but the work was carried on by his compatriot, Choukevitch,7 who
clearly described zones of inhibition induced by some of these
bacteria on agar plates of cholera organisms. He then tried to use
some of them in experimental cholera in the rabbit, but without
success. Still, this was a very interesting and a reasonably well-
thought-out essay in the employment of the antagonistic properties
of bacteria for therapeutic purposes.
106THERAPEUTIC USE OF MICRO-ORGANISMS
We have up to the present been concerned with the products
of bacteria, but as long ago as 1917 Greig-Smith2' in Australia made
the first clear-cut observation on the antagonistic effects of actino-
mycetes towards certain bacteria. In 1924 Gratia and Dath20 dis-
covered an actinomycete which had the power of dissolving certain
pathogenic organisms, and subsequently they performed many
experiments on this and other antibiotic organisms. They used a
particular actinomycete to dissolve certain pathogenic organisms
such as staphylococci for the production of vaccines which they
called mycolysates. This, as you will realize, was an idea similar
to that proposed by Nicolle using the B. subtilis. It is not an
example of the direct use of substances produced by micro-organisms
for the treatment of infection, but rather substances are employed
to obtain a product suitable for immunization. Actually, these
mycolysates, although used fairly extensively in Belgium, have
never come into general use in medicine. Much27 and Kimmel-
stiel,23 about the same time, proposed to use a strain of B. mycoides
for the same purpose, and put dissolved organisms for vaccination
purposes on the market under the name of "sentocym."
We will now consider the products produced by fungi or
moulds. It was in 1896 that Gosio18 an Italian, described the pro-
duction of a crystalline substance from a Penicillium which was
being investigated as a possible cause of pellagra. This substance,
which is now known as mycophenolic acid, was shown by Gosio to
inhibit the growth of anthrax bacilli. But no animal experiments
were done, owing to the minute amounts of the substance available.
Similar observations were made in the United States by Alsberg and
Black in 1912,1 who isolated from another Penicillium a substance
which they called penicillic acid, not to be confused with penicillin.
This, they found, would stop the growth of Bact. coli, but they also
noted that the substance was very toxic to animals.
The first instance of the use of fungal products for the treatment
of disease is probably the work of Vaudremer, who in 1913
reported39 on the treatment of tuberculosis in animals with the
products of Aspergillus fumigatus. He went on to use filtrates
from the growth of A. fumigatus for intravenous injections into
man. More than 200 cases were treated, from which he con-
cluded that the material used was innocuous, since it did not provoke
any febrile reactions. He was not sure, however, that any thera-
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peutic effect had been produced. It was evident that Vaudremer
was trying to obtain a direct lethal effect on the tubercle bacillus by
injecting intravenously the metabolic products of Aspergillus
fumigatus.
It would be a mistake to believe that all the observations on
bacterial and fungal antagonisms were made by those interested in
medicine-quite the contrary. It is impossible for me today to
consider in any detail the great volume of work contributed by
workers in the botanical field and I shall have to be content with
mentioning only a few observati,ons. Very clear descriptions, for
example, of 'the inhibition of the growth of certain fungi by a bac-
terium were given by Reinhardt in 1893,36 and he also described
inhibitions produced by Penicillia and Aspergilli. An illustration in
the work of Harder, published in 1912, shows the inhibition of
Stereum purpureunm by Penicillium lutetrn, and again an illustration
in Porter's work, published in 1924,33 is of particular interest, for
it shows colonies of a Penicillium inhibiting the growth of Pesta-
lozzia, whereas growing on the surface of Pestalozzia are other col-
onies of a Penicillium which have no inhibitory effects.
The most famous inhibition of this nature, of course, was that
described by Fleming in 1929.'5 He observed that an accidental
contaminant, subsequently identified as Penicillium notatum, pro-
duced lysis of colonies of staphylococcus growing on a plate. He
subcultured this mould and found -that it conferred powerful antibac-
terial powers to the broth on which it had grown. He called the
broth in which this antibacterial' substance had been secreted "peni-
cillin," and later the antibacterial substance itself was given this
name. He observed that it acted on many important pathogenic
organisms, such as the streptococcus and staphylococcus, while others,
such as H. influenzae and the Salmonellas, remained unaffected.
The crude metabolism liquid was shown to 'be no more toxic to
animals than broth in which nothing had grown. No curative
experiments were performed on experimental infection in animals,
but the suggesti'on was made that the substance would be useful for
dressing septic lesions in man, and indeed some were so treated
without, however, any very striking results. The clinical possibili-
ties of this antibiotic were not pursued until the beginning of the
next decade, although Fleming maintained his strain of the mould
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and made use of the broth in differential culture media in the
laboratory.
One of the most interesting series of experiments on fungal
antagonists was done by Weindling, who noticed that 'Trichoderma
ligiorun produced a lethal principle which inhibited the growth
of Rhizoctonia solani. Subsequently in 1936 Weindling and Emer-
son succeeded in isolating this substance, now known as "gliotoxin,"
in crystalline form. Its properties were examined in considerable
detail by many investigators and it has proved to be quite unsuitable
for any general chemotherapeutic purpose, but as it affects certain
fungi pathogenic to man it may be of use for skin diseases. It is,
however, the first good example of a work being carried through
from the initial detection of an antagonism to the isolation in crystal-
line form of the antagonist, with subsequent examination of this
product.
In the 1920's a new idea, which has yet to be developed, was
introduced by Schiller.37 He brought forward evidence that yeasts
and possibly other organisms could be trained to produce substances
that were antagonistic to certain bacteria by growing them on media
in which the only source of nitrogen was the bodies of the bacteria
it was desired to antagonize. He claimed that in such experiments
yeasts developed a thermolabile inhibitory substance which might
be of value in therapeutics. He called the phenomenon "induced"
antagonism, in contradistinction to the "neutral" antagonisms. This
interesting idea has as yet received no real confirmation, in fact,
some authors do not believe it is valid, but it nevertheless seems to
be worth a careful re-examination.
At this juncture I should like to call your attention to the fact
that a good deal of progress in the antibiotic field depends on the
development of adequate techniques. We are apt to think perhaps
that all these techniques are of great origin, but an excellent paper,
previously mentioned, published by Frost"6 in 1904, contained a
description of seven methods, some of which are employed to this
day. One of the more interesting involves the suspensi-on of broth
in a collodion sac inside a flask containing more broth. He planted
organisms in the broth in the flask and observed whether diffusible
inhibitory substances were produced which passed through the col-
lodion and stopped the growth of sensiltive organisms in the sac.
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Frost's paper deserves study by those particularly interested in the
subject of antibiosis.
The suggestions and experiments on the use of micro-organisms
for therapeut7ic purposes up to 1939 may be summarized as follows:
1. The replacement of a pathogenic organism by another and
less harmful organism-for example, "Bact. termo" to replace the
'tubercle bacillus in the lungs; staphylococci to replace diphtheria
bacilli, pneumococci to replace meningococci in the throat, and lactic
acid bacilli and Bact. coli to replace organisms infecting the intestine.
2. Artificial immunization by one organism to protect against
infection by another.
3. The use of lytic substances from one organism for the
preparation of soluble vaccines of other species-for example,
Much's sentocym and Gratia's mycolysates.
4. The use of soluble bacterial or mould products by parenteral
injection to treat established diseases-for example, pyocyanase in
anthrax, and Vaudremer's extracts of Aspergillus fumigatus and
Rappin's extracts of B. subtilis in tuberculosis. These were
examples of true chemotherapeutic use.
5. The use of soluble bacterial or mould products as a topical
application for the treatment of local infections-for example, pyo-
cyanase and penicillin broth.
In 1939 Dubosl° published his first important paper on a sub-
stance isolated from a spore-forming organism, B. brevis. This
substance which is now known as "tyrothricin" subsequently received
very extensive investigation both from a bacteriological and from
a chemotherapeutic angle. Although tyrothrycin was shown to be
an effective product for application locally to infected wounds, its
great toxicity precluded its use for generalized infections. Never-
theless, this work of Dubos and his associates marked a new level
in the investigation of antibiotics for therapeutic purposes.
Shortly after, in 1940, the first paper recording the discovery
of the chemotherapeutic properties of penicillin was published from
Oxford.' These observations clearly distinguished penicillin from
any antibiotic previously described. The Oxford work showed,
after a long series of experiments, both chemical and biological, that
artificial infections in mice with streptococcus, staphylococcus, and
Cl. septique could be completely controlled by the subcutaneous
injection of a penicillin extract, so that there was almost 100 per
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cent survival from infections which otherwise would certainly have
been fatal. In other words, penicillin was a chemothera-
peutic drug of great power, that is to say, it was of such low toxicity
that it could, without producing any toxic signs, be injected by
parenteral routes in amounts which would stop the growth of bac-
teria in all parts of the body. Based on these experimental results
on animals penicillin was carried to the clinic with, as you are all
aware, some very satisfactory results. The point I wish to empha-
size is that the discovery that one of the antibiotics was a real
chemotherapeutic agent with some very remarkable and almost
miraculous properties was the starting point for investigations in
almost every country in the world in a search for other chemothera-
peutic agentts.
We now have records of the existence of many hundreds of
substances of potential interest. Those extracted from fungi have
almost without exception proved to be extremely toxic. Many
species of both Penicillia and Aspergilli are known to produce peni-
cillin-like substances, which perhaps are identical with some of the
already known penicillins. There is a group of moulds which pro-
duce antibacterial substances of a phenolic type, for example,
mycophenolic acid from Penicillium brevi compactum, citrinin from
Penicillium citrinum, and penicillic acid from Pencillium cyclopium.
Although the inhibitions produced by some moulds appear to be
very similar under the microscope they are due to chemically dis-
tinct substances. The work of isolating and examining these sub-
stances proceeds, but I will not weary you with a long list of these
very toxic products. Other than penicillin, only one mould product
whose properties bring it within the realm of being considered a
chemotherapeutic agent has so far been discovered-thait is helvolic
acid produced from Aspergillus fumigatus mut. Ielvola. It is a
crystalline substance composed only of carbon, hydrogen, and
oxygen. It is stable to boiling at pH 2, the free acid is insoluble,
though the sodium salt is readily soluble. It has relatively low
acute toxicity but continued doses produce fatty degeneration of the
liver. Nevertheless, it has been possible to afford a certain degree
of protedtion in mice infected with streptococci or staphylococci.
It is, however, unlikely to be used in medicine for a number of
reasons which I have not the time to develop.
Aside from the great number of Penicillia and Aspergilli that
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have now been at least partially investigated, attention is being paid
to the Basidiomycetes to w'hich a large number of the fungi belong.
The fruits or sporophores of this type of fungus have in many
instances been found to contain antibacterial substances which can
be extracted by grinding up the sporophore with sand and physiolo-
gical saline. Some of these fungi have been grown in artificial cul-
ture and the active principles have been isolated in a crystalline
form, but so far they have all proved very toxic.
There are, of course, many points of difficulty arising in the
cultivation, not only of the Basidiomycetes bu't also of the Penicillia
and Aspergilli, for example, the media on which they grow are of
the greatest importance. Experiments have been conducted in
growing a single species of fungus on six different media; on only
two of 'them was an antibiotic produced, on three there was nothing,
and on one a growth-promoting substance seemed to have been
elaborated. This will give you perhaps sonie idea of the elaborate
nature of even preliminary investigations into the production of
antibiotics.
At the present time most interest is focussed around the group
of organisms known as Actinomycetes. Waksman and his collabora-
tors40 have been investigating this great group of organisms for
many years. They first succeeded in isolating the very toxic sub-
stance known as actinomycin. Later they found a more interesting
agen't known as streptothricin which had chemotherapeutic properties
against certain Gram-negative organisms, but it proved too toxic
for use in man; finally in 1944 they prepared "streptomycin,"
which bids fair to become a very important chemotherapeutic agent,
since its *toxicity is low and its efficiency in animal infections has
been clearly established. At present its use in man is 'being thor-
oughly explored with results which appear in many instances to
carry great promise. Streptomycin is active against Gram-negative
organisms which are unaffected by penicillin; and what is possibly
much more important, the tubercle bacillus is affected by it both
in vitro and in vivo. We are certainly going to hear a great deal
more of this substance.
From the Actinomycetes, too, comes "proactinomycin," an agent
that came from an accidental contaminant isolated in the laboratory
and upon which we have been working in Oxford. Like strepto-
mycin it is a base, but is mainly active against Gram-positive organ-
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isms. It just comes into the realm of chemotherapeutic agents, for it
has been shown possible to prot-ect a proportion of mice infected with
streptococci by doses of proactinomycin given by mouth. It is,
however, quite unlikely to be used in medicine as its toxicity appears
to be too great, and the chemotherapeutic effects not sufficiently
marked. Thus, it can be seen that this group of organisms has
already produced substances of the greatest interest. Whether
others will be found remains to be seen.
Bacteria are also being actively investigated as a source of anti-
bacterial agents. We have seen howthe spore-formers have already
produced tyrothrycin. Recently another substance which has been
called "bacitracin" has been isolated from a strain of B. subtilis. In
animal experiments this substance has been shown to have clear-cut
chemotherapeutic properties. It is active against the same range of
organisms as is penicillin, but little has yet been published concerning
its properties.
Another substance which is probably different from bacitracin
has also been isolated from B. subtilis and designated "subtilin."
This, apparently, has chemotherapeutic properties too. I, myself,
believe that the group of spore-forming organisms probably pro-
duces a large number of different antibiotics, but only further inves-
tigation can clarify this field. It is possible that some of the
products will be of value in medicine. Although much attention
has been devoted to the spore-formers, it is well to remember that
other bacteria also produce antibacterial substances. And I should
just like to say a few words about that produced by Bact. coli.
Gratia in 192519 described the existence of one 'strain of Bact. coli
which was capable of inhibiting the growth of another strain of the
same organism. He gave a description of some of its properties
but the substance was not isolated. I have a special interest in
substances produced by Bact. coli, for in 1929 I first personally
encountered the phenomenon of antibiosis in that organism (isolated
from cat feces) which we found to produce a substance that inhibited
Micrococcus lysodeikticus. Recently Heatley and I have investi-
gated the properties of the substance produced by a similar organ-
ism recently isolated from cat feces. When streaks of this organ-
ism have been grown on agar containing glucose and cross streaks
of various organisms have been put on the same plate, we have
found that all the organisms are inhibited in the neighborhood of
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the streak of Bact. coli. When a few drops of blood are added to
the medium, only one organism, which is a strain of Bact. coli, is
inhibited. The first inhibition is due to the production of hydrogen
peroxide, while the inhibition in the second case is due to some other
substance. This inhibition can be produced in fluid culture only
when large volumes of air are continuously blown through the
medium. It has proved very difficult to extract because it is not
soluble in any of the usual organic solvents, but it has been possible
to produce a highly purified and active preparation -of a highly
specific nature. When the liquid is put on a plate of Bact. coli,
resistant colonies are observed. These colonies by all the ordinary
bacteriological tests do not differ from those which have been pre-
vented from growing. It is not active against all strains of Bact.
cols, but it does inhibit the growth of Shiga and some dysentery
organisms and so far is not effective against 'other bacteria tested.
It is thus highly specific against certain Gram-negative organisms
but does not affect Gram-positive bacteria. It has very little
toxicity, as much as 18 mg. being injected into a mouse without
causing noticeable symptoms. It is very active under certain con-
ditions for it will inhibit the growth of Bact. coli at a dilution of
1 in 60,000,000, but this effect is greatly dependent upon the size
of the inoculum studied. It has no chance whatever of being a
chemotherapeutic agent, h.owever, as it 's rapidly destroyed by
trypsin, pepsin, and by slices of such tissues as kidney and liver;
after injections of large amounts none, or practically none, appears
in the urine. This perhaps will give you some glimpse of the fact
that it is necessary to perform really comprehensive tests, many of
them on animals, before an antibacterial agent, even though it
appears to be non-toxic, can be ascertained to be of use in medicine.
This one clearly stands no chance of it. There is no doubt that
there are many other interesting substances to be extracted from
bacteria and studied.
Another source which has been particularly investigated in this
University is that of the lichens by Burkholder et al.4 They
have found that many lichens produce antibacterial substances. To
date none of them, as far as I know, has been shown to have chemo-
therapeutic properties, and for this reason it appears at the moment
unlikely that they will be of value in medicine, yet there are, no
doubt, many antibacterial substances produced by this form of life.
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Another great source of antibacterials are *the flowering plants.
These have considerable historical interest because the herbalists
from antiquity have used extracts of various parts of plants for
application to infected wounds and other diseased parts of the body.
Many thousands of plants have now been tested by grinding up
their flowers, leaves, seeds, etc., with sand and water, and these
extracts have been shown to contain powerful antibacterial sub-
stances. Favorable results were obtained with extracts of garlic, a
species of spirea, and buttercups, but one plant, known as "self-heal"
and highly recommended by medieval herbalists, proved to have no
antibacterial effect. One of the most interesting substances which
we have examined is that coming from the common wallflower.
Compresses made from the leaves of this plant have been recom-
mended from Roman times so that it is interesting to find that
extracts of the leaves, flowers, and seeds all contain a powerful anti-
bacterial substance which, on extraction, has been shown to be cheiro-
line. This is a crystalline mustard oil containing a sulphone group.
It is quite a powerful antiseptic, but of no value chemotherapeuti-
cally because intravenous injections cause epileptiform fits. Never-
theless, it is of considerable interest to know that the old herbalists
had succeeded in finding a strong antiseptic in many ways superior
to carbolic acid so long used by surgeons.
This subject has now become so vast and the amount of informa-
tion at our disposal so great that I have in this lecture done little
more than indicate to you its scope. I hope that you now realize
that there has been a long history to which hundreds of workers
have contributed, that we know of the existence of many hundreds
of substances, a few of which may be of considerable use in medicine.
Even the possibility that some of these substances may be of use in
disease conditions other than infections must be explored. It is a
vast work which holds much interest to those engaged in it.
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